What are the clinical features, diagnostic criteria, and management recommendations for Prune‑1 syndrome (PRUNE1‑related neurodevelopmental disorder)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

PRUNE1-Related Neurodevelopmental Disorder (PRUNE1 Syndrome)

PRUNE1 syndrome is a severe autosomal recessive neurodevelopmental disorder requiring early genetic diagnosis through exome or genome sequencing, with management focused on multidisciplinary supportive care targeting seizure control, spasticity, feeding dysfunction, and respiratory complications to reduce mortality and optimize quality of life.

Clinical Features

Core Neurological Manifestations

The disorder presents with a consistent constellation of severe neurological features 1, 2:

  • Global developmental delay (universal finding) - profound and evident by 2-6 months of age
  • Bilateral spastic paresis with axial hypotonia and peripheral spasticity
  • Seizures (79% of cases) - epileptic spasms are most common, with drug-resistant epilepsy in 47% 3
  • Dysphagia requiring feeding support, often necessitating gastrostomy
  • Progressive microcephaly - though NOT universal (contrary to earlier reports), present in majority but not required for diagnosis 1

Movement Disorders and Extrapyramidal Features

Prominent dystonia and bradykinesia are increasingly recognized as key features, particularly with splice-site variants 4. Peripheral neuropathy is documented in approximately 40% of cases 1.

Dysmorphic Features

A recognizable facial gestalt includes 5, 2:

  • Frontal bossing and dolichocephaly
  • Low-set, malformed ears
  • Thick eyebrows and broad nasal bridge
  • Thick lips

Neuroimaging Findings

Brain MRI demonstrates 1, 2:

  • Progressive cerebral and cerebellar atrophy
  • T2-hyperintense brainstem lesions
  • Thin corpus callosum
  • Delayed myelination
  • Ventricular dilation (may be present prenatally)

Systemic Complications

  • Respiratory insufficiency requiring ventilatory support in severe cases
  • Feeding dysfunction necessitating gastrostomy in many patients
  • Recurrent aspiration due to dysphagia

Diagnostic Approach

When to Suspect PRUNE1 Syndrome

Consider this diagnosis in infants presenting with:

  1. Severe hypotonia with emerging spasticity by 2-4 months
  2. Prenatal or postnatal ventricular dilation
  3. Dysmorphic features as described above
  4. Early-onset seizures, particularly epileptic spasms
  5. Prominent dystonia with pyramidal signs 4

Genetic Testing Strategy

First-tier testing: Exome sequencing (ES) or whole genome sequencing (WGS) should be performed immediately when clinical suspicion exists 6. This aligns with 2021 ACMG guidelines recommending ES/WGS as first- or second-tier testing for unexplained developmental delay/intellectual disability with congenital anomalies 6.

Do not delay genetic testing for metabolic workup unless specific metabolic indicators are present. The 2020 AAP guidelines support immediate genetics referral for complex neurodevelopmental presentations 6.

Molecular Spectrum

The most common pathogenic variant is c.316G>A (p.Asp106Asn) in the DHH domain, particularly prevalent in Turkish and Middle Eastern populations 3, 5. Other variants include:

  • Missense mutations in DHH and DHHA2 phosphodiesterase domains
  • Splice-site variants (c.132+2T>C) causing in-frame deletions or premature truncation 4
  • Contiguous gene deletions encompassing PRUNE1 1

All reported cases show autosomal recessive inheritance with homozygous variants, reflecting high consanguinity rates in affected populations.

Pathophysiology

The DHH motif mutations impair manganese ion binding, resulting in diminished enzymatic activity 3. This leads to:

  • Disrupted microtubule polymerization
  • Impaired neuronal migration and proliferation
  • Neuronal hyperexcitability contributing to epileptogenesis 3

Management Recommendations

Seizure Management

Epilepsy treatment is challenging with 47% developing drug-resistant epilepsy 3. EEG monitoring shows heterogeneous epileptic activities and diffuse background slowing. Aggressive antiepileptic therapy is warranted, though specific medication efficacy data are limited. Consider early epilepsy surgery evaluation for refractory cases.

Spasticity and Movement Disorders

  • Baclofen (oral or intrathecal) for spasticity management
  • Botulinum toxin injections for focal dystonia
  • Physical therapy to prevent contractures (knee contractures develop early) 5

Feeding and Nutrition

Early gastrostomy placement should be considered proactively given universal dysphagia and aspiration risk. Do not delay nutritional support waiting for oral feeding improvement.

Respiratory Support

Monitor closely for respiratory insufficiency. Some patients require tracheostomy for chronic ventilatory support 1.

Surveillance Protocol

  • Neuroimaging: Serial brain MRI every 6-12 months to monitor progressive atrophy
  • EEG: Regular monitoring for seizure activity
  • Neurological assessment: Every 3-6 months for progression of spasticity and movement disorders
  • Nutritional status: Growth parameters at each visit
  • Peripheral nerve studies: If neuropathy suspected

Prognosis and Counseling

The disease course is progressive in all patients 1. Mortality is significant, with approximately 33% dying in the first or early second decade of life 1. Death typically results from respiratory complications, aspiration pneumonia, or refractory seizures.

Genetic Counseling

  • 25% recurrence risk for future pregnancies in carrier parents
  • Prenatal diagnosis available through amniocentesis or chorionic villus sampling
  • Preimplantation genetic diagnosis is an option for known familial variants

Critical Pitfalls to Avoid

  1. Do not exclude PRUNE1 syndrome based on absence of microcephaly - this is not universal 1
  2. Do not perform extensive metabolic workup before genetic testing unless specific indicators present
  3. Do not delay gastrostomy placement - early intervention prevents aspiration complications
  4. Do not underestimate seizure severity - epileptic spasms require aggressive treatment
  5. Recognize splice-site variants when dystonia is prominent 4

Note: Evidence 7, 6 provides guideline framework for rare genetic neurodevelopmental disorders but does not contain PRUNE1-specific recommendations. Evidence 8, 9, 10 discusses different conditions (PURA-NDD, PPP1R21-NDD, and Prune-Belly Syndrome respectively) and were not incorporated as they are unrelated to PRUNE1 neurodevelopmental disorder.

References

Related Questions

What oral dose of torsemide or bumetanide (Bumex) is equivalent to 60 mg IV furosemide (Lasix)?
What is the recommended management for a patient with 8/10 lumbar pain, including confirmatory medial‑branch blocks using a dual‑comparative technique and interim multimodal analgesic therapy?
What could cause persistent daytime appetite and repeated nighttime hunger episodes with normal blood glucose levels in a patient who only notices the hunger upon waking?
In a patient with obstructive sleep apnea who is adherent to CPAP therapy, how should persistent nighttime hunger or increased appetite be evaluated and managed?
What pain management strategies and medication dosing are recommended for a patient with chronic kidney disease stage 3 (eGFR 30‑59 mL/min/1.73 m²)?
What is the clinical significance and recommended management for an asymptomatic adult with a direct bilirubin level of 0.3 mg/dL and otherwise normal liver function tests?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.